YHB Investment Advisors Inc. lifted its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,052 shares of the medical research company’s stock after buying an additional 402 shares during the quarter. Amgen comprises 1.3% of YHB Investment Advisors Inc.’s portfolio, making the stock its 22nd biggest holding. YHB Investment Advisors Inc.’s holdings in Amgen were worth $7,661,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC grew its position in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after purchasing an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after purchasing an additional 489,720 shares in the last quarter. BlackRock Inc. grew its position in shares of Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after purchasing an additional 909,689 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Amgen by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock worth $1,522,551,000 after purchasing an additional 140,117 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares in the last quarter. 78.03% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Monday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $132,259.19, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 2.19 and a beta of 1.42. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $2.89 earnings per share. equities research analysts predict that Amgen, Inc. will post 13.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. Amgen’s payout ratio is 205.45%.
Amgen announced that its Board of Directors has authorized a share buyback plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its stock is undervalued.
AMGN has been the subject of several research analyst reports. Vetr cut Amgen from a “buy” rating to a “hold” rating and set a $184.25 price target for the company. in a report on Wednesday, January 3rd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $189.00 price objective on shares of Amgen in a research note on Wednesday, January 24th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a research note on Friday, October 27th. Finally, Cann reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $191.84.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the sale, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.